Citations

Mayo Clinic

Showing 10 of 108572 citations.

Thrombosis risk with haemoglobin C trait and haemoglobin C disease: A systematic review
Jacobs, Jeremy W. , Sharma, Deva , Stephens, Laura D. , Rinder, Henry M. , Wheeler, Allison P. , Gerberi, Dana , Goel, Ruchika , Tormey, Christopher A. , Booth, Garrett S. , Bloch, Evan M. , Adkins, Brian D. , Rinder, Henry M , Wheeler, Allison P , Goel, Ruchika , Tormey, Christopher A , Booth, Garrett , Bloch, Evan M , Adkins, Brian David , Jacobs, Jeremy W , Stephens, Laura , Villalba, Cristina A. Figueroa , Woo, Jennifer S.

British Journal of Haematology | January 31, 2024 | Volume: 204 | Issue: 4 | Pages: 1500-1506

10.1111/bjh.19313 | PMID 38291731 Get It

SummaryThe thrombotic risk with haemoglobin C trait (HbAC) or haemoglobin C disease (HbCC) is unclear. However, individuals with HbCC have demonstrated chronic haemolysis, higher blood viscosity and altered rheology when compared to individuals with wild‐type haemoglobin (HbAA). These physiological alterations may theoretically translate to increased risk of thrombosis; therefore, a systematic literature review was performed to investigate the possible association between HbAC and/or HbCC and thrombosis. Twenty‐two studies met inclusion criteria representing 782 individuals with HbAC (n = 694) or HbCC (n = 88). Fifteen studies described the presence/absence of venous thromboembolism (VTE) in patients with HbAC (n = 685) or HbCC (n = 79), while seven studies described patients with HbAC (n = 9) or HbCC (n = 9) and arterial thrombosis. Most (n = 20) studies were case reports or case series; however, two studies suggested a potential increased VTE risk with HbAC compared to HbAA in (i) all patients (OR 2.2, 95% CI: 0.9–5.5) and in (ii) pregnant individuals (RR 3.7, 95% CI 0.9–16). This review is the largest assessment of patients with HbC trait or disease and thrombosis to date; despite its limitations, the findings suggest HbC may be a predisposing risk factor to thrombosis. Prospective cohort studies are warranted to definitively elucidate the risk of thrombosis in this population.
Dynamic Prognosis Prediction for Patients on DAPT After Drug‐Eluting Stent Implantation: Model Development and Validation
Li, Fang , Rasmy, Laila , Xiang, Yang , Feng, Jingna , Abdelhameed, Ahmed , Hu, Xinyue , Sun, Zenan , Aguilar, David , Dhoble, Abhijeet , Du, Jingcheng , Wang, Qing , Zhang, Xinyuan , Xie, Ziqian , Nian, Yi , He, Jianping , Zhou, Yujia , Li, Jianfu , Prosperi, Mattia , Bian, Jiang , Zhi, Degui , Niu, Shuteng , Dang, Yifang , Zhang, Xinyuan , Xie, Ziqian , Nian, Yi , He, JianPing , Zhou, Yujia , Li, Jianfu , Prosperi, Mattia , Bian, Jiang , Zhi, Degui , Tao, Cui , Sun, Zenan , Li, Fang , Niu, Shuteng , Dang, Yifang , Tao, Cui

Journal of the American Heart Association | January 31, 2024 | Volume: 13 | Issue: 3 | Pages: No page available

10.1161/jaha.123.029900 | PMID 38293921 Get It

Background The rapid evolution of artificial intelligence (AI) in conjunction with recent updates in dual antiplatelet therapy (DAPT) management guidelines emphasizes the necessity for innovative models to predict ischemic or bleeding events after drug‐eluting stent implantation. Leveraging AI for dynamic prediction has the potential to revolutionize risk stratification and provide personalized decision support for DAPT management. Methods and Results We developed and validated a new AI‐based pipeline using retrospective data of drug‐eluting stent‐treated patients, sourced from the Cerner Health Facts data set (n=98 236) and Optum's de‐identified Clinformatics Data Mart Database (n=9978). The 36 months following drug‐eluting stent implantation were designated as our primary forecasting interval, further segmented into 6 sequential prediction windows. We evaluated 5 distinct AI algorithms for their precision in predicting ischemic and bleeding risks. Model discriminative accuracy was assessed using the area under the receiver operating characteristic curve, among other metrics. The weighted light gradient boosting machine stood out as the preeminent model, thus earning its place as our AI‐DAPT model. The AI‐DAPT demonstrated peak accuracy in the 30 to 36 months window, charting an area under the receiver operating characteristic curve of 90% [95% CI, 88%–92%] for ischemia and 84% [95% CI, 82%–87%] for bleeding predictions. Conclusions Our AI‐DAPT excels in formulating iterative, refined dynamic predictions by assimilating ongoing updates from patients' clinical profiles, holding value as a novel smart clinical tool to facilitate optimal DAPT duration management with high accuracy and adaptability.
Optimizing treatment environments for trait sensitivity in eating disorders
Peterson, Carol B. , Weber, E. , Sim, Leslie , Weber, Elise

Eating Disorders | January 31, 2024 | Volume: 32 | Issue: 3 | Pages: 325-339

10.1080/10640266.2024.2306429 | PMID 38291724 Get It

Abortion Advocacy During COVID-19: A Commentary on the Experiences of Physicians from Four Countries
Talbott, Jennifer , Solomon, Tess, Sepúlveda, Lilian , Chavkin, Wendy , Talbott, Jennifer M V , Sepúlveda, Lilian

No container title available | January 31, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.170669115.57877739/v1 Get It

Granulomatosis with polyangiitis with primary vaginal involvement and ureteral obstruction: A case report and systematic review of the literature
Pereira, Augusto , Magrina, Javier F. , Magtibay, Paul M. , Stamps, Beatriz G., Muñoz-Nuñez, Elena, Pereira Sánchez, Augusto , Pérez‐Medina, Tirso

No container title available | January 31, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.170668497.74330451/v1 Get It

Background: Granulomatosis with polyangiitis (GPA) is a vasculitis with multi-organ involvement. Some cases of gynecologic involvement have been described, but there are no systematic reviews in the literature. Objectives: to provide a systematic review of the literature of GPA patients with gynecological involvement. Search Strategy: PubMed and Embase, were searched from inception to July 2012 for GPA patients with gynecological involvement Medical Subject Headings (MeSH) and free-text terms. Selection Criteria: Patients with GPA and primary gynecologic involvement, and/or genital recurrence. Exclusion criteria were other language, review articles, pregnancy, fertility or male patients. Data Collection and Analysis: Data were extracted on clinical evolution, symptoms, examinations findings, diagnosis delay, treatment, outcome, patient status, and follow-up. The main limitation of the studies was the high heterogeneity, which resulted in a narrative review and could lead to publication bias. Main Results: Seventeen studies included data from patients with GPA and primary or relapsed gynecological involvement. In GPA patients, the genitourinary system is affected in <1%. 61% of the authors of this review thought the patient had cancer. The main gynecological symptom is bleeding, but exclusive gynecologic symptomatology is rare (ENT: 63%, lungs: 44%, kidneys-urinary tract: 53%). GPA could affect all areas of the genital tract, but the most frequent location is the uterine cervix. Medical treatment for GPA is effective. Conclusions: GPA of the female genital tract must be considered when biopsies of an ulcerated malignant-appearing cervical or vaginal mass are negative for malignancy even when they are unspecific. Rheumatology consultation is indicated.
Breakthrough SARS-CoV-2 infections after vaccination: A critical review
Afshar, Zeinab Mohseni, Barary, Mohammad , Mansouri, Feizollah , Ebrahimpour, Soheil , Nazary, Kosar, Carson‐Chahhoud, Kristin , Barary, Mohammad , Carson-Chahhoud, Kristin , Afshar, Zeinab Mohseni , Sio, Terence T. , Sullman, Mark J. M. , Babazadeh, Arefeh

No container title available | January 31, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.170668473.38426771/v1 Get It

At the beginning of the current pandemic, it was believed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection would induce lifelong immunity and that reinfections would be unlikely. However, after several cases of reinfection were documented in previously infected patients, this was understood to be a false assumption, and this waning humoral immunity has raised significant concerns. Accordingly, long-term and durable vaccine-induced antibody protection against infection have also become a challenge, as several breakthroughs of COVID-19 infection have been identified in individuals who were fully vaccinated. This review discusses the current evidence on breakthrough COVID-19 infections occurring after vaccination.
Commentary
Kumbhari, Vivek

Endoscopy | January 30, 2024 | Volume: 56 | Issue: 02 | Pages: 156-156

10.1055/a-2209-3002 | PMID 38290504 Get It

Germline 3q21 Deletion Affects GATA2 and is Associated with Myelodysplastic Syndrome
Greenmyer, Jacob R. , Thompson, Whitney, Hoppman, Nicole L., Khan, Shakila P. , Patnaik, Mrinal M. , Kohorst, Mira A. , Schimmenti, Lisa A.

No container title available | January 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.170667237.71385774/v1 Get It

Germline 3q21 chromosome deletions result in a rare multi-system condition. Of the 14 cases of germline 3q21 deletion syndrome reported, 2 have been reported to develop myelodysplastic syndrome necessitating allogeneic HCT (our patient and one other). Our patient was treated with an allogeneic, matched sibling hematopoietic cell transplantation. Patients with 3q21 deletion have a predilection for myelodysplastic syndrome, likely due to GATA2 deletion. We recommend frequent complete blood count evaluation with annual bone marrow aspiration to monitor for development of MDS in patients with 3q21 deletion.
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results
Yacoub, Abdulraheem , Borate, Uma , Rampal, Raajit K. , Ali, Haris , Gerds, Aaron T. , Kremyanskaya, Marina , Winton, Elliott F., Goel, Swati , Schiller, Gary J. , McCloskey, James, Palmer, Jeanne , Holmes, Houston, Hager, Steven, Assad, Albert , Erickson‐Viitanen, Susan, Zhou, Feng , Gerds, Aaron T , Goel, Swati , Oh, Stephen T , Palmer, Jeanne M , Daver, Naval , Wang, Eunice S. , Hobbs, Gabriela , O'Connell, Casey Lee , Oh, Stephen T. , Daver, Naval

Blood Advances | January 30, 2024 | Volume: 8 | Issue: 6 | Pages: 1515-1528

10.1182/bloodadvances.2023011620 | PMID 38290135 Get It

Abstract Ruxolitinib reduces spleen volume, improves symptoms, and increases survival in patients with intermediate- or high-risk myelofibrosis. However, suboptimal response may occur, potentially because of signaling via the phosphoinositide 3-kinase (PI3K)/protein kinase B pathway. This phase 2 study evaluated dosing, efficacy, and safety of add-on PI3Kδ inhibitor parsaclisib for patients with primary or secondary myelofibrosis with suboptimal response to ruxolitinib. Eligible patients remained on a stable ruxolitinib dose and received add-on parsaclisib 10 or 20 mg, once daily for 8 weeks, and once weekly thereafter (daily-to-weekly dosing; n = 32); or parsaclisib 5 or 20 mg, once daily for 8 weeks, then 5 mg once daily thereafter (all-daily dosing; n = 42). Proportion of patients achieving a ≥10% decrease in spleen volume at 12 weeks was 28% for daily-to-weekly dosing and 59.5% for all-daily dosing. Proportions of patients achieving ≥50% decrease at week 12 in Myelofibrosis Symptom Assessment Form and Myeloproliferative Neoplasms Symptom Assessment Form symptom scores were 14% and 18% for daily-to-weekly dosing, and 28% and 32% for all-daily dosing, respectively. Most common nonhematologic treatment-emergent adverse events were nausea (23%), diarrhea (22%), abdominal pain and fatigue (each 19%), and cough and dyspnea (each 18%). New-onset grade 3 and 4 thrombocytopenia were observed in 19% of patients, each dosed daily-to-weekly, and in 26% and 7% of patients dosed all-daily, respectively, managed with dose interruptions. Hemoglobin levels remained steady. The addition of parsaclisib to stable-dose ruxolitinib can reduce splenomegaly and improve symptoms, with manageable toxicity in patients with myelofibrosis with suboptimal response to ruxolitinib. This trial was registered at www.clinicaltrials.gov as #NCT02718300.